Holen Sie sich die Stockscreener-App
4.32
2.13%
0.10
Schlusskurs vom Vortag:
$4.22
Offen:
$4.34
24-Stunden-Volumen:
24,467
Relative Volume:
0.21
Marktkapitalisierung:
$1.53B
Einnahmen:
$842.96M
Nettoeinkommen (Verlust:
$-185.63M
KGV:
-8.2145
EPS:
-0.5259
Netto-Cashflow:
$-228.52M
1W Leistung:
-3.36%
1M Leistung:
+0.00%
6M Leistung:
+24.93%
1J Leistung:
-42.76%
1-Tages-Spanne:
$4.295
$4.35
1-Wochen-Bereich:
$4.21
$4.47
52-Wochen-Spanne:
$2.85
$7.98
Evotec Se Adr Stock (EVO) Company Profile
Vergleichen Sie EVO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EVO
Evotec Se Adr
|
4.30 | 1.53B | 842.96M | -185.63M | -228.52M | -0.5259 |
|
ZTS
Zoetis Inc
|
167.97 | 75.15B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.61 | 47.71B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.96 | 47.70B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.41 | 18.75B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
131.27 | 13.96B | 612.78M | -86.37M | -62.91M | -0.87 |
Evotec Se Adr Stock (EVO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-07 | Herabstufung | Jefferies | Buy → Hold |
| 2024-08-08 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2024-07-29 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-07-11 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2024-04-12 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-01-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-06-23 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-06-16 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-06-08 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-04-04 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-12-09 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-11-16 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2022-08-10 | Herabstufung | Morgan Stanley | Overweight → Underweight |
| 2022-03-02 | Fortgesetzt | Cowen | Outperform |
| 2022-01-07 | Fortgesetzt | Citigroup | Neutral |
Alle ansehen
Evotec Se Adr Aktie (EVO) Neueste Nachrichten
Evotec: Some Recovery Has Come, But Much More Is Expected - Seeking Alpha
Evotec shares surge 20% on Halozyme's 2 billion euro takeover bid - MSN
In-Vitro Toxicology Testing Market Projected to Reach USD 30.06 Bn by 2033 - GlobeNewswire Inc.
Markets Brief: Are Bank Stocks Expensive? - Morningstar
Evotec SE withdraws acquisition offer By Investing.com - Investing.com South Africa
Evotec SE withdraws acquisition offer - Investing.com India
Halozyme ends bid to acquire Evotec at €2 billion valuation - Investing.com
Halozyme outlines plan to acquire Evotec for €2 billion - Investing.com
Halozyme outlines plan to acquire Evotec for €2 billion By Investing.com - Investing.com UK
Halozyme to Fund Proposed Evotec Takeover in Cash, CEO Says - Yahoo Finance
Evotec SE responds to media speculation - Investing.com India
Large Pharma Partner Halozyme Therapeutics Offers To Acquire Germany-Based Evotec For ~$2 Billion - AOL
Halozyme Therapeutics sinks after confirming $2B Evotec buyout offer - Seeking Alpha
Evotec SE responds to media speculation By Investing.com - Investing.com UK
Halozyme proposes $2 billion acquisition of Evotec - Investing.com India
Earnings call: Evotec SE maintains 2024 outlook amid strategic changes - Investing.com India
Evotec SE ADR earnings beat by $0.02, revenue fell short of estimates - Investing.com
Evotec Reports Strategic Growth Amidst Revenue Challenges - TipRanks
Evotec SE Reports 9M 2024 Results: Strategic Progress and Successful Expansion Amid Challenging Market Conditions - Yahoo Finance
Evotec stock outlook clouded by strategy update delays, warns Jefferies - Investing.com
KZIAKazia Therapeutics Limited American Depositary Shares Latest Stock News & Market Updates - StockTitan
Stock Information - Evotec
Annual General Meeting - Evotec
Investor Relations - Evotec
Bristol Myers' German Partner Evotec Plans Layoffs, Cites 'Challenging Revenues, Profitability' - Yahoo Finance
Dozens of US Stocks Are Newly Undervalued After Market Selloff - Morningstar
Evotec shares crash 36% on profit warning - Investing.com
T. Rowe Price Raises Stake in Evotec SE - TipRanks
Evotec (EVO) Inks Drug Discovery Collaboration Deal With J&J - Yahoo Finance
Together for Medicines That MatterEvotec - Evotec
Evotech and Roche subsidiary Genentech enter into drug discovery alliance - Proactive Investors USA
Finanzdaten der Evotec Se Adr-Aktie (EVO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.49%
1.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):